Mar 09, 2021 9:15 am EST Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
Mar 04, 2021 9:00 am EST Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
Feb 01, 2021 9:15 am EST Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
Jan 19, 2021 9:15 am EST Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
Jan 12, 2021 9:05 am EST Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Dec 29, 2020 9:15 am EST Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
Nov 24, 2020 7:30 am EST Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
Nov 12, 2020 4:01 pm EST Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 09, 2020 9:15 am EST Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19
Nov 05, 2020 9:00 am EST Capricor Therapeutics to Present Third Quarter 2020 Financial Results and Recent Corporate Update on November 12